Branded PPI denied as not FDA-approved for this use by Aetna?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna's specific coverage criteria for branded ppi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Aetna angle on Branded PPI
## Why Aetna May Deny a Branded PPI as Not FDA-Approved
A "not FDA-approved" denial for a branded PPI most commonly arises in one of three scenarios: (1) the drug is being prescribed for an indication not listed in its FDA-approved labeling (off-label use); (2) there is a documentation or coding error in the prior-authorization submission that does not match an approved indication; or (3) the specific formulation, route of administration, or combination product does not carry FDA approval for the submitted diagnosis. The denial is often correctable once the exact mismatch is identified.
## Federal Appeal Rights
For off-label use denials, ACA §2719 and the ERISA §503 full-and-fair review standard both require that the plan's clinical criteria be disclosed and applied consistently. Many state insurance codes and plan documents explicitly require coverage of off-label use supported by a recognized compendium (such as DrugDex or NCCN) or peer-reviewed literature. The external-review window is generally four months from the final internal denial. Expedited review is available for urgent clinical situations.
## Appeal Process and Timeline
1. Identify the exact basis of the not-FDA-approved denial — request Aetna's written explanation citing which indication or formulation issue triggered the denial. 2. Verify the submitted diagnosis code against the FDA-approved indications in the prescribing label; a coding correction alone sometimes resolves the denial administratively. 3. File the internal appeal with corrected documentation or off-label-use evidence within the plan's deadline. 4. Escalate to external review if the internal denial is upheld.
## Documentation to Gather
- FDA-approved prescribing label for the specific branded PPI: confirm whether the patient's indication is listed; if not, this is an off-label appeal.
- Compendia citations: entries in a recognized drug compendium supporting the off-label use, if applicable.
- Prescriber letter: a detailed statement linking the patient's confirmed diagnosis to the requested use, citing supporting clinical evidence and explaining why approved alternatives are inadequate.
- Diagnostic records: all records establishing the clinical indication — endoscopy reports, pathology, imaging, specialist notes.
- Correct procedure and diagnosis codes: verify that the submitted ICD-10 and NDC/procedure codes align with the intended indication before refiling.
## Criteria-Mapping Strategy
Obtain the full FDA prescribing label from DailyMed (dailymed.nlm.nih.gov) and Aetna's Clinical Policy Bulletin for off-label drug coverage. Map each coverage criterion to a specific piece of evidence. If the denial is based on a coding mismatch rather than a true off-label scenario, document that correction explicitly in the appeal cover letter.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →